{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T05:05:44Z","timestamp":1779771944437,"version":"3.53.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mosunetuzumab is a CD20\u00d7CD3 bispecific antibody approved for adult relapsed or refractory follicular lymphoma. Post-marketing evidence on its safety profile remains scarce. This pharmacovigilance study used the Food and Drug Administration Adverse Event Reporting System (FAERS)to characterize real-world adverse event (AE) signals associated with mosunetuzumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed disproportionality analysis using reports from the FAERS database spanning from the first quarter of 2004 to the fourth quarter of 2025. The primary analysis set encompassed reports wherein mosunetuzumab was coded as the Primary Suspect (PS). Disproportionality analyses were performed using four algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma poisson shrinker (MGPS). After excluding implausible records, the time to onset (TTO)for AEs was summarized using the median and interquartile range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1154 FAERS reports mentioning mosunetuzumab were included in the primary analysis. 3 positive signals were identified at the System Organ Class (SOC)level. Cytokine release syndrome (CRS), neutropenia, tumour flare and infection-related events were frequently reported signals at the Preferred Term (PT)level. Additional disproportionate reporting signals were noted for cardiac events and eye disorders, including atrial fibrillation, uveitis. Of 310 reports with valid dates, most AEs occurred within 30 days following treatment initiation, whereas a nontrivial proportion was reported at \u2265180 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study offers real-world evidence for guiding the clinical use of mosunetuzumab. It highlights the necessity for clinicians to monitor for AEs during treatment by recognizing potential adverse reaction signals beyond those documented in the current prescribing information.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1809879","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:47:29Z","timestamp":1779770849000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety profile of mosunetuzumab: a pharmacovigilance study based on the food and drug administration adverse event reporting system"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiahui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Health Statistics, School of Public Health, Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Health Statistics, School of Public Health, Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Evidence-Based Medicine, Shanxi Bethune Hospital, Academy of Medical Sciences, Tongji Shanxi Hospital","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Hospital of Shanxi Medical University","place":["Taiyuan, China"]},{"name":"Research Center for Hemostatic Disorders and Hematologic Malignancies, Shanxi Medical University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"105009","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinaemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e13825","DOI":"10.1111\/cts.13825","article-title":"Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed\/refractory B-cell Non-Hodgkin lymphoma","volume":"17","author":"Bender","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/01.all.0000173787.65777.77","article-title":"Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy?","volume":"5","author":"Br\u00f6nnimann","year":"2005","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.hoc.2020.02.001","article-title":"Epidemiology of follicular lymphoma","volume":"34","author":"Cerhan","year":"2020","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"B6","article-title":"Bispecific antibody toxicity","volume-title":"Statpearls. Treasure Island (FL)","author":"Chennapragada","year":"2024"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1159\/000369963","article-title":"Conjunctival follicular lymphoma after treatment for invasive squamous cell carcinoma","volume":"5","author":"da Cunha","year":"2014","journal-title":"Case Rep. Ophthalmol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1182\/bloodadvances.2024015274","article-title":"Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma","volume":"9","author":"Danilov","year":"2025","journal-title":"Blood Adv."},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/10428194.2024.2404246","article-title":"Persistent parvovirus B19 infection in a heavily pretreated lymphoma patient receiving mosunetuzumab","volume":"66","author":"F\u00fcreder","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"B12","doi-asserted-by":"publisher","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10147-024-02662-5","article-title":"Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed\/refractory follicular lymphoma: FLMOON-1","volume":"30","author":"Goto","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1517\/14740338.4.5.929","article-title":"The role of data mining in pharmacovigilance","volume":"4","author":"Hauben","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2023.0394","article-title":"Does your unwell patient have haemophagocytic lymphohistiocytosis?","volume":"85","author":"Holloway","year":"2024","journal-title":"Br. J. Hosp. Med. (Lond)."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/ajh.26737","article-title":"Follicular lymphoma: 2023 update on diagnosis and management","volume":"97","author":"Jacobsen","year":"2022","journal-title":"Am. J. Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/medicina62020342","article-title":"Bispecific antibodies in B-Cell lymphomas: mechanisms, efficacy, toxicity, and management","volume":"62","author":"J\u00f3na","year":"2026","journal-title":"Med. Kaunas."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40265-022-01749-5","article-title":"Mosunetuzumab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/14740338.2024.2412234","article-title":"Exploring SGLT-2 inhibitors and sarcopenia in FAERS: a post-marketing surveillance study","volume":"25","author":"Kuai","year":"2026","journal-title":"Expert Opin. Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/14712598.2024.2404079","article-title":"Mosunetuzumab for the treatment of follicular lymphoma","volume":"24","author":"Labanca","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00428-022-03432-2","article-title":"Follicular lymphoma and marginal zone lymphoma: how many diseases?","volume":"482","author":"Laurent","year":"2023","journal-title":"Virchows Arch."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1182\/bloodadvances.2025017914","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory Richter's transformation","volume":"10","author":"Lewis","year":"2026","journal-title":"Blood Adv."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70211","DOI":"10.1111\/cts.70211","article-title":"Ethnic sensitivity assessment of mosunetuzumab pharmacokinetics and pharmacodynamics in Chinese patients with relapsed or refractory follicular lymphoma","volume":"18","author":"Li","year":"2025","journal-title":"Clin. Transl. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"100810","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab safety profile in patients with relapsed\/refractory B-cell non-hodgkin lymphoma: clinical management experience from a pivotal phase I\/II trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.medcli.2021.03.041","article-title":"Follicular lymphoma: an update on diagnosis, prognosis, and management. Actualizaci\u00f3n en el diagn\u00f3stico, pron\u00f3stico y tratamiento del linfoma folicular","volume":"157","author":"Mozas","year":"2021","journal-title":"Med. Clin. Barc."},{"key":"B27","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1093\/jjco\/hyad082","article-title":"Dose-escalation part of phase I study of single-agent mosunetuzumab in Japanese patients with relapsed\/refractory B-cell Non-Hodgkin lymphoma","volume":"53","author":"Munakata","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","article-title":"Cardiovascular toxicities associated with novel cellular immune therapies","volume":"8","author":"Munir","year":"2024","journal-title":"Blood Adv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/bjh.18504","article-title":"Decreased serum phosphate levels are a useful biomarker to predict occurrence and severity of cytokine release syndrome in chimeric antigen receptor T-cell therapy","volume":"200","author":"Nakamura","year":"2023","journal-title":"Br. J. Haematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaophthalmol.2014.376","article-title":"Ocular adnexal follicular lymphoma: a multicenter international study","volume":"132","author":"Rasmussen","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1177\/10781552251355433","article-title":"Mosunetuzumab-associated fatal HHV-6 encephalitis in a patient with follicular lymphoma","volume":"31","author":"Samperio","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B32","doi-asserted-by":"publisher","first-page":"e008518","DOI":"10.1136\/jitc-2023-008518","article-title":"Cardiovascular toxicities associated with bispecific T-cell engager therapy","volume":"12","author":"Sayed","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3390\/jpm15020051","article-title":"The development and application of bispecific antibodies in B-Cell non-hodgkin lymphoma","volume":"15","author":"Sun","year":"2025","journal-title":"J. Pers. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00277-025-06206-3","article-title":"Epcoritamab-induced fatal pleural effusion in diffuse large B-Cell lymphoma: a case report and literature review","volume":"104","author":"Takahata","year":"2025","journal-title":"Ann. Hematol."},{"key":"B35","first-page":"1b","article-title":"Application of multivariate probabilistic (bayesian) networks to substance use disorder risk stratification and cost estimation","volume":"6","author":"Weinstein","year":"2009","journal-title":"Perspect. Health Inf. Manag."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1809879\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:47:37Z","timestamp":1779770857000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1809879\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":35,"alternative-id":["10.3389\/fphar.2026.1809879"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1809879","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"article-number":"1809879"}}